Autistic Disorder: Clinical Trials

161 trials for Autistic Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

105 completed, 13 recruiting, 11 terminated, 11 withdrawn. 161 Phase 2, 24 Phase 1, 18 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2161Completed 105, Recruiting 13, Terminated 11, Withdrawn 11, Unknown 8, Not yet recruiting 7, Active not recruiting 5, Enrolling by invitation 1
Phase 124Completed 14, Unknown 4, Not yet recruiting 3, Enrolling by invitation 1, Terminated 1, Withdrawn 1
Phase 318Completed 12, Not yet recruiting 2, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Autistic Disorder: new trials by email Literature Review of Autistic Disorder trials Research Report on Autistic Disorder

Trials (filtered) newest first · largest first

All 161 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism
Ganaxolone (Ztalmy), Placebo - Autism in Children, Autistic Disorder in Children and Adolescents
Phase 2Not yet recruitingStanford University662027-01-012026-11-05
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
Role of Omega-DEK in Childhood Apraxia of Speech
Omega-DEK, L-carnitine, Placebo - Childhood Apraxia of Speech, Verbal Apraxia
Phase 2Not yet recruitingClaudia R. Morris342026-11-012026-07-29
TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS
PPF3, Placebo - Autism Disorder
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital1002026-10-012026-10-29
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Everolimus blinded oral capsules, Placebo - Cowden's Disease, Cowden's Syndrome
Phase 2 / Phase 3Not yet recruitingBoston Children's Hospital602026-09-012026-06-04
A Placebo-controlled Trial of Folinic Acid in Children With ASD
Folinic Acid, Placebo - Autism Spectrum Disorder
Phase 2RecruitingProf. Adi Aran1502026-06-232026-06-22
Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism
Phase 1 / Phase 2Enrolling by invitationBlack Tie Medical, Inc.502026-04-302026-04-27
Xenon Therapy for Children With Autism Spectrum Disorder
Xenon - Autism Spectrum Disorder (ASD), Autism
Phase 1 / Phase 2Not yet recruitingThe Children's Hospital of Zhejiang University School of Medicine722026-03-012026-02-27
Enhancing Orthographic Communication and Literacy Outcomes for AAC Learners
ALLSTAR - Literacy, Communication, Nonverbal
Phase 1 / Phase 2Not yet recruitingPenn State University602026-03-012026-02-03
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
Propranolol, Placebo - Autism Spectrum Disorder, Challenging Behaviour
Phase 2RecruitingJeremy Veenstra-vanderweele602026-01-302026-09-01
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
Terpenes-Enriched CBD-Predominant Oil, Placebo, Terpenes-Enriched CBD Oil (THC-Free) - Autism, Autism Spectrum Disorder
Phase 2RecruitingBazelet Nehushtan LtD.782025-10-052025-11-19
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo - Autism Spectrum Disorder
Phase 2RecruitingNew York State Psychiatric Institute302025-10-012026-09-02
Treatment Planning for ABA Employing Auxiliary Tools V2+ (TREAAT2+)
Tech-enabled ABA treatment planning - Autism Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingMontera Health Texas LLC202025-07-012024-11-22
Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults
MB-IMP, Placebo - Autism Spectrum Disorder, Anxiety
Phase 2RecruitingSouthwest Autism Research & Resource Center1082025-05-282026-03-30
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Sertraline, Placebo - Neurodevelopmental Disorders, Autism
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital1302024-09-162026-07-27
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Low Dose ARD-501, High Dose ARD-501, Placebo - Autism Spectrum Disorder
Phase 2CompletedAardvark Therapeutics, Inc.52024-08-012025-05-09
Safety and Efficacy of tPBM for Epileptiform Activity in Autism
noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - Autism Spectrum Disorder, EEG With Periodic Abnormalities
Phase 2CompletedRichard Frye62024-07-012026-09-22
Trial of Zolpidem for Sleep in Children With Autism
Zolpidem, Placebo - Autism, Autism Spectrum Disorder
Phase 2RecruitingStanford University262023-08-092026-03-27
Trial of Diphenhydramine for Sleep in Children With Autism
Diphenhydramine, Placebo - Autism, Autism Spectrum Disorder
Phase 2RecruitingStanford University262023-08-092026-03-27
Trial of Suvorexant for Sleep in Children With Autism
Suvorexant, Placebo - Autism, Autism Spectrum Disorder
Phase 2RecruitingStanford University262023-08-092026-03-27

Showing 20 of 161. Sign in to see all of them.

Narrower conditions

Autism Spectrum Disorder (72)  ·  Asperger Syndrome (18)  ·  Child Development Disorders, Pervasive (17)  ·  Anxiety Disorders (9)  ·  Fragile X Syndrome (8)  ·  Communication (4)  ·  Epilepsy (4)  ·  Tuberous Sclerosis (4)  ·  Aggression (3)  ·  Attention Deficit Disorder with Hyperactivity (3)  ·  Intellectual Disability (3)  ·  Learning Disabilities (3)  ·  Neurodevelopmental Disorders (3)  ·  Obsessive-Compulsive Disorder (3)

Broader conditions

Mental Disorders (159)  ·  Neurodevelopmental Disorders (158)  ·  Child Development Disorders, Pervasive (144)  ·  Autism Spectrum Disorder (89)  ·  Nervous System Diseases (22)  ·  Neurologic Manifestations (20)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18)  ·  Neurobehavioral Manifestations (18)  ·  Genetic Diseases, Inborn (17)  ·  Heredodegenerative Disorders, Nervous System (15)  ·  Behavior (14)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (14)  ·  Congenital Abnormalities (13)  ·  Genetic Diseases, X-Linked (11)

Interventions

Oxytocin (7)  ·  Everolimus (5)  ·  Memantine (5)  ·  Risperidone (4)  ·  arbaclofen placarbil (4)  ·  Acetylcysteine (3)  ·  Aripiprazole (3)  ·  Cognitive Behavioral Therapy (3)  ·  Donepezil (3)  ·  Sertraline (3)  ·  Valproic Acid (3)  ·  trofinetide (3)  ·  Buspirone (2)  ·  Cannabidiol (2)  ·  Carnitine (2)

Sponsors

Stanford University (12)  ·  Forest Laboratories (5)  ·  Holland Bloorview Kids Rehabilitation Hospital (5)  ·  National Institute of Mental Health (NIMH) (5)  ·  University of California, San Francisco (5)  ·  University of North Carolina, Chapel Hill (5)  ·  Arizona State University (3)  ·  Boston Children's Hospital (3)  ·  Neuren Pharmaceuticals Limited (3)  ·  Seaside Therapeutics, Inc. (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Chugani, Diane C. (2)  ·  Drexel University College of Medicine (2)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)  ·  Evdokia Anagnostou (2)

Countries

United States (122)  ·  Canada (10)  ·  Israel (7)  ·  France (6)  ·  Italy (4)  ·  Spain (4)  ·  Australia (3)  ·  Belgium (3)  ·  Colombia (3)  ·  Estonia (3)  ·  Hungary (3)  ·  Iceland (3)  ·  New Zealand (3)  ·  Poland (3)  ·  Serbia (3)

Top investigators

Linmarie Sikich, MD (6)  ·  Antonio Hardan, MD (4)  ·  Antonio Y. Hardan, MD (4)  ·  Alexander Kolevzon, MD (3)  ·  Evdokia Anagnostou, M.D. (3)  ·  James B. Adams, PhD (3)  ·  Jeremy Veenstra-VanderWeele, MD (3)  ·  Jordan Lateiner, MS, MBA (3)  ·  Richard P Malone, MD (3)  ·  Robert L Hendren, DO (3)  ·  Alan Percy, MD (2)  ·  Antonio Y. Hardan, M.D. (2)  ·  Bryan King, MD (2)  ·  Craig Erickson, MD (2)  ·  Ephraim Katz, PhD (2)

Results publications

PMID 37811711, PMID 36006807, PMID 37460385, PMID 38363467, PMID 18315448, PMID 19148734, PMID 19309326, PMID 19487623, PMID 20145986, PMID 20406576, PMID 20683766, PMID 21883204, PMID 22151477, PMID 22342106, PMID 23097920, PMID 23216716, PMID 23357440, PMID 23782126, PMID 23978163, PMID 24061784, PMID 24356715, PMID 24472253, PMID 24849255, PMID 25187257, PMID 25526831, PMID 25685306, PMID 25818246, PMID 25878901, PMID 26746121, PMID 26889605, PMID 27752075, PMID 28374207, PMID 28503116, PMID 28696286, PMID 30196397, PMID 30287612, PMID 31217257, PMID 32660869, PMID 32902182, PMID 33536055, PMID 33927413, PMID 34543081, PMID 34644471, PMID 34658941, PMID 34693989, PMID 35093163, PMID 35395866, PMID 35594551, PMID 36353577, PMID 37011526

NIH funding

P50HD109861 (3), 2009 (1), 2017 (1), 5KL2TR001109-05 (1), P50HD055784 (1), P50MH100023 (1), R01HD091972 (1), R01MH072263 (1), R01MH073524 (1), R21MH064941 (1), R21MH080026 (1), R21NS043979 (1), R34HD065274 (1), R34MH100276 (1), U01HD073984 (1)